Please assess the completion status of the following clinical trial:

Trial Title: Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who had a kidney transplant performed greater than or equal to 28 days prior to enrollment~* At least 1 identified, suitably matched Posoleucel (ALVR105) cell line for infusion is available.~* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.~* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.~Exclusion Criteria:~* Undergone allogeneic hematopoietic cell transplantation~* Evidence or history of graft versus host disease (GVHD) or cytokine release syndrome (CRS).~* Uncontrolled or progressive bacterial or fungal infections~* Known or presumed pneumonia~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose \>0.5 mg/kg/day or equivalent).~* Pregnant or lactating or planning to become pregnant.~* Weight \<40 kg.~* Patients who received, or planned to receive abatacept or belatacept, within 3 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel (Type: EXPERIMENTAL): Arm 1: Regimen A
- Posoleucel and Placebo (Type: EXPERIMENTAL): Arm 2: Regimen B
- Placebo (Type: PLACEBO_COMPARATOR): Arm 3: Regimen A

Based on this trial design, predict the completion outcome and termination type (if applicable).